Connor, Clark & Lunn Investment Management (CC&L)’s PDL BioPharma, Inc. PDLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-2,167,755
Closed -$6.83M 1094
2020
Q3
$6.83M Sell
2,167,755
-803,221
-27% -$2.57M 0.05% 255
2020
Q2
$8.65M Sell
2,970,976
-764,710
-20% -$2.42M 0.06% 221
2020
Q1
$10.5M Sell
3,735,686
-271,650
-7% -$876K 0.09% 150
2019
Q4
$13M Sell
4,007,336
-379,702
-9% -$1.1M 0.09% 160
2019
Q3
$9.48M Sell
4,387,038
-100,546
-2% -$269K 0.07% 181
2019
Q2
$14.1M Sell
4,487,584
-503,889
-10% -$1.63M 0.09% 159
2019
Q1
$18.6M Sell
4,991,473
-899,178
-15% -$3.04M 0.12% 131
2018
Q4
$17.1M Sell
5,890,651
-77,454
-1% -$213K 0.12% 133
2018
Q3
$15.7M Buy
5,968,105
+290,458
+5% +$713K 0.09% 160
2018
Q2
$13.3M Buy
5,677,647
+887,945
+19% +$2.48M 0.07% 185
2018
Q1
$14.1M Buy
4,789,702
+1,143,153
+31% +$3.12M 0.09% 165
2017
Q4
$9.99M Buy
3,646,549
+1,032,437
+39% +$3.17M 0.06% 204
2017
Q3
$8.86M Buy
2,614,112
+1,126,399
+76% +$3.13M 0.05% 222
2017
Q2
$3.67M Buy
1,487,713
+88,765
+6% +$204K 0.02% 304
2017
Q1
$3.18M Buy
1,398,948
+40,073
+3% +$88.6K 0.02% 317
2016
Q4
$2.88M Sell
1,358,875
-36,200
-3% -$101K 0.02% 325
2016
Q3
$4.67M Sell
1,395,075
-21,800
-2% -$69.2K 0.03% 254
2016
Q2
$4.45M Buy
1,416,875
+3,200
+0.2% +$10.7K 0.03% 254
2016
Q1
$4.71M Buy
1,413,675
+22,000
+2% +$68.6K 0.04% 234
2015
Q4
$4.93M Buy
1,391,675
+315,525
+29% +$1.32M 0.04% 211
2015
Q3
$5.41M Buy
1,076,150
+901,050
+515% +$5.16M 0.04% 190
2015
Q2
$1.13M Buy
+175,100
New +$1.17M 0.01% 318
2014
Q3
Sell
-98,340
Closed -$1.01M 625
2014
Q2
$1.01M Buy
+98,340
New +$876K 0.01% 321
2014
Q1
Sell
-112,434
Closed -$1.01M 849
2013
Q4
$1.01M Sell
112,434
-113,261
-50% -$954K 0.01% 367
2013
Q3
$1.85M Sell
225,695
-98,000
-30% -$788K 0.02% 206
2013
Q2
$2.64M Buy
+323,695
New +$2.52M 0.03% 167

Other funds holding PDLI